Now Wegovy shows potential in COVID-19

Novo Nordisk’s (NOV: N) semaglutide - marketed under the names Wegovy and Ozempic - have already shown their potential to treat diabetes, obesity, cardiovascular (CV) conditions and maybe even reduce aging, too.

A new analysis, presented at the annual European Society of Cardiology (ESC) meeting and simultaneously published in the Journal of the American College of Cardiology, suggests that the GLP –1 receptor agonist could mitigate COVID-19 severity, too.

This has been shown after the SELECT study, which was designed to measure the drug’s impact in obese patients with established CV disease but without diabetes, was adapted to capture COVID-19 data as well.